首页> 中文期刊> 《中国药师》 >别嘌呤醇用药调查及其药疹患者HLA-B*5801基因型分析

别嘌呤醇用药调查及其药疹患者HLA-B*5801基因型分析

         

摘要

Objective: To analyze the allopurinol medication and HLA-B * 5801 genotype of the patients with drug eruption after administration.Method: A prospective analysis was used to study epidemiological characteristics of the patients administered allopurinol in our hospital.The patients with drug eruption possibly caused by allopurinol, especially severe ones, were monitored.The blood samples were collected to analyze HLA* B5801 genotype.Result: There were 421 patients administrated allopurinol altogether.The mean dose of allopurinol was 145.8 mg·d-1.Only four cases were diagnosed as drug eruption caused by allopurinol and among them,only one patients showed HLA-B * 5801 positive by the PCR-SSP test.Conclusion: The patients with hyperuricemia or gout in our hospital were generally elder people, whose allopurinol dosage was less than the maximum dosage for adults with lower incidence of serious rash.The definite relationship between HLA-B * 5801 genotype and severe rash induced by allopurinol has not shown in the study which should be researched further.%目的:调查别嘌呤醇用药情况并分析可能引起别嘌呤醇皮疹的HLA-B*5801基因型.方法:收集我院应用别嘌呤醇患者的人口流行病学特征,分析发生皮疹患者的HLA-B*5801基因型.结果:监测服用别嘌呤醇患者421名,别嘌呤醇平均剂量145.8 mg·d-1.4例患者分别出现单纯斑丘疹、结节性药疹、慢性荨麻疹和大疱型类天疱疮等药疹,其中仅1例患者检测出HLA-B*5801.结论:我院患者别嘌呤醇用药剂量小于成人最大量,严重药疹发生率低,HLA-B*5801与别嘌呤醇致严重皮疹的相关性有待进一步确证.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号